

AD-A192 775

ARMED FORCES RADIOBIOLOGY
RESEARCH INSTITUTE
SCIENTIFIC REPORT
SR87-49

4

From: PROSTAGLANDIN AND LIPID METABOLISM
IN RADIATION INJURY

Edited by Thomas L. Walden, Jr. and Haywood N. Hughes
(Plenum Publishing Corporation, 1987)

DTIC FILE COPY

A PARADOXICAL ROLE FOR EICOSANOIDS:
RADIOPROTECTANTS AND RADIOSENSITIZERS

T. L. Walden, Jr.

Department of Radiation Biochemistry
Armed Forces Radiobiology Research Institute
Bethesda, Maryland 20814-5145

DTIC
ELECTE
MAR 21 1988
S H D

ABSTRACT

Understanding the radiobiology of eicosanoids is complicated by their ability to act as mediators of damage and recovery and as radioprotective agents. Changes in the tissue concentrations of eicosanoids following irradiation are dependent on several factors, including the type of eicosanoid, time postirradiation, radiation dose, and other contributing mediators and enzyme changes in the surrounding microenvironment. Many of these same prostaglandins and the leukotrienes have been shown to be radioprotective when given before irradiation. (Reprints)

INTRODUCTION

The eicosanoids are a group of biological mediators that have received attention in the field of radiobiology as mediators of radiation injury (1-3) and recently as radioprotective agents (4-6). They are metabolites of arachidonic acid (Figure 1), an essential 20-carbon fatty acid containing four unsaturated double bonds (7). Arachidonic acid is primarily esterified in the second position of the glycerol backbone of phospholipids in the cell membranes. Ultraviolet and ionizing radiation stimulate the release of free arachidonic acid through the action of phospholipases (8-10). Increased calcium concentrations also stimulate the phospholipase release of arachidonic acid. Following arachidonic acid release, one of three events occurs (outlined in Figure 1): (a) re-esterification of the free arachidonic acid back into the cell membrane, or (b) and (c) metabolism through the arachidonic acid cascade. Arachidonic acid is metabolized (Figure 1) through either the cyclooxygenase pathway (B), leading to the formation of prostaglandins, thromboxane, and prostacyclin, or the lipoxygenase pathway (C), leading to the formation of leukotrienes, lipoxins, and hydroxy fatty acids. These compounds have a number of important physiological roles in vasoregulation, smooth muscle regulation, electrolyte balance, and neuroregulation, as well as pathological roles in inflammation, fever, pain, and shock (reviewed in reference 7).

DISTRIBUTION STATEMENT A

Approved for public release;
Distribution Unlimited

263

88 3 18 062

Reproduced From
Best Available Copy




Fig. 1. Arachidonic acid cascade. Radiation stimulates release of free arachidonic acid from phospholipids of cell membrane. Once released, arachidonic acid may be (a) re-esterified back into cell membrane, (b) metabolized through cyclooxygenase pathway, or (c) metabolized through lipoxygenase pathway. Compounds that block either pathway may be exerting a beneficial effect by inhibiting production of a particular eicosanoid or by shunting more arachidonic acid into products of other pathway.

PROSTAGLANDINS IN RADIATION INJURY

The role of prostaglandins in radiation injury has been recently reviewed (11). Irradiation has been shown to alter tissue prostaglandin levels, producing both elevations (12-17) and decreases (1,17,18). The response following irradiation depends on dose received (18,19), tissue irradiated (1,13-19), and time of determination postirradiation (1). Some radiation-induced alterations in prostaglandin synthesis may persist for months after exposure to radiation or, conversely, may not become altered until several months postexposure (12). Prostaglandin changes following irradiation have been demonstrated *in vitro* in fibroblasts (11), endothelial cells (20), tissue slices, homogenates (21,22), and urine (23). Several effects of radiation on prostaglandin metabolism in the blood vessels are summarized in Figure 2. Alteration of tissue prostaglandin levels may result from either anabolic or catabolic processes, or from combinations of the two. Exposure of minipig skin to X radiation results in the increased production of prostaglandin E₂ (PGE₂) over the first 24 hours postirradiation (13). Early PGE₂ elevation in X-irradiated minipig skin is followed by a progressive decrease in PGE₂, which corresponds to an increase in prostaglandin F₂ (PGF₂) tissue levels. These latter processes are the result of an increase in 9-keto prostaglandin reductase, an enzyme that converts PGE₂ to PGF₂. There is an association between alterations in the spleen prostaglandin levels of

irradiated mice and alterations in the activity of prostaglandin dehydrogenase (24), an enzyme responsible for prostaglandin inactivation. Increases in prostaglandin E_1 (PGE_1) in the spleen postirradiation are caused by decreased enzymatic catabolism, leading to accumulation.

A role for prostaglandins as mediators of radiation injury has been suggested in experiments using cyclooxygenase-inhibiting drugs, such as indomethacin (3) or aspirin (2,25), to reduce specific radiation-induced inflammatory responses. These experiments indicate that prostaglandins contribute to radiation-induced ocular tissue inflammation in rabbits (2), mucositis in humans (14), esophagitis in opossums (3), and gastrointestinal syndrome in mice (26). Prostaglandins may mediate inflammation through increased extravasation, vasoregulation, and fever and as chemotactic factors for phagocytic white blood cells (reviewed recently in references 7,27). Radiation may also affect the ability of the receptor to bind the prostaglandin and induce a specific function. The specific binding of prostaglandin E_2 is decreased in the spleens and small intestines of irradiated mice (28). The effects of indomethacin on alteration of whole animal survival are contradictory, and have been shown to either enhance survival (29) or have no effect (30). The reasons for the different responses to nonsteroidal anti-inflammatory drugs are not




Fig. 2. A: Effects of radiation on prostaglandin metabolism by blood vessels. This figure presents a brief summary and is based on observations observed in human umbilical arteries (ref. 18) and in mouse spleen (ref. 24). B: Prostaglandin effects on blood vessels. Radiation induces an alteration of prostaglandin concentrations. These compounds may be either vasodilatory or vasoconstrictive, depending on class of prostaglandin released, particular vascular site, and prostaglandin concentration. As indicated, they may induce synthesis of other mediators or act as chemotactic agents.



For

I ☒

d ☐

ton ☐

by Codes

Dist and/or Special

A-1 20

known, but one may speculate that they are related to the dosage and schedule of administration.

PROSTAGLANDINS AND LEUKOTRIENES IN RADIOPROTECTION

Paradoxically, the prostaglandins have pathological roles in damage, but they also function as radioprotectants for cells in culture (6,31) and hematopoietic and intestinal stem cells (4) *in vivo*, and also enhance whole animal survival (5). Several studies on prostaglandin-induced modification of radiosensitivity in cell culture provide evidence that protection may be associated with elevations in cyclic AMP (6,31). These studies have centered on the use of PGE_1 , a potent cAMP stimulus. For prostaglandin enhancement of whole animal survival from otherwise lethal exposure to ionizing radiation, the processes are more complicated, and the basic underlying mechanism(s) remains unknown. The most effective prostaglandin in terms of whole animal survival (31; Walden et al., submitted) is 16,16-dimethyl prostaglandin E_2 (DiPGE_2) (Figure 3), an analog of the naturally occurring prostaglandin E_2 . Misoprostil, an analog of PGE_1 , appears to be more effective for protection of the intestinal crypt cells (32). DiPGE_2 has a biological half-life in the tens of minutes (5), as illustrated and explained in Figure 3. The naturally occurring prostaglandin E_2 has a half-life of 2 minutes (7). Forty μg of DiPGE_2 /mouse (1.6 mg/kg body weight) enhances the $\text{LD}_{50/30}$ of mice exposed to cobalt-60 gamma radiation, providing a dose modification factor of 1.72 (5). Radioprotection by eicosanoids is both time and dose dependent, and must be




Fig. 3. Inactivation of prostaglandin E_2 but not 16,16-dimethyl prostaglandin E_2 (DiPGE_2). Prostaglandin E_2 in vasculature is normally inactivated by lung through action of prostaglandin dehydrogenase. Methyl groups in 16 position of DiPGE_2 prevent this inactivation step from occurring at 15 position, extending biological half-life. DiPGE_2 is primarily inactivated by liver (ref. 39).

administered just prior (approximately 15 min) to irradiation (5,33; Walden et al., submitted). There does not appear to be a common vascular end point induced by radioprotective eicosanoids, since some are vasodilatory and others are vasoconstrictive, and there is no general effect on the hematocrit (Walden et al., submitted). Pharmacological studies indicate that the DiPGE₂ protection results from the parent analog rather than a metabolite. However, the optimal period of radioprotection does not correlate with the optimal concentrations of DiPGE₂ in the tissue (5).

A decrease in locomotor activity (33) is produced by radioprotective concentrations of DiPGE₂. The optimal time for protection (5-60 min) is shorter than the duration of the locomotor behavior decrement (33). A marked depression of the locomotor activity occurred within 5 min postadministration of 10 μ g DiPGE₂/mouse or greater. The behavior of DiPGE₂-treated mice returns to control levels by 6 hours following a 10- μ g DiPGE₂ dose and 30 hours following a 40- μ g dose (33). Diarrhea is another undesirable effect of some but not all of the radioprotective eicosanoids (Walden et al., submitted). It may be possible in the future to separate the detrimental effects without a decrease in protective efficacy.

Most work on the radiobiology of arachidonic acid metabolites to date has centered on the prostaglandins, primarily because the standards and radioimmunoassay kits for analyses are commercially available. Arachidonic acid may also be metabolized by the lipoxygenase pathway (Figure 1) to form leukotrienes and hydroxy fatty acids. Ultraviolet-B irradiation of human skin produced a threefold elevation of 12-hydroxy eicosatetraenoic acid 24 hours postirradiation, although no changes in leukotriene B₄ levels were observed (34). Leukotriene C₄, a thiol ether of glutathione and the triene-containing 20-carbon backbone, is elevated in the plasma of mice receiving hematoporphyrin derivative-induced phototherapy (400- to 410-nm wavelength radiation) and may be related to mast cell degranulation (35). Leukotriene C₄ modifies the radiosensitivity of V79A03 Chinese hamster cells in culture (36). Two-hour pretreatment with 2.5 μ M leukotriene C₄ doubles the number of cells surviving a subsequent X irradiation (reproductive survival, based on colony formation). This protection is concentration dependent and appears to be associated with specific leukotriene C₄-binding sites on the cell surface. Leukotriene C₄ also induces radioprotection and enhances the LD50/30 of mice (Walden, submitted).

Future research directions in eicosanoid radioprotection need to focus on the mechanism of action for this novel class of biological mediators/radioprotective agents. Effective radioprotective concentrations of arachidonic acid metabolites are in the μ g/animal range (1.6 μ g/kg body weight) (4,5), compared to mg/mouse (200-800 mg/kg body weight) required for the classical thiol radioprotectants. Several mechanisms may be involved in protection. The role of specific receptor activation provides the opportunity to enhance and control the protection. If a primary component of protection is receptor mediated, it may be possible to selectively protect all normal tissues that have receptors, but not those normal and tumor tissues that lack the receptor. Eicosanoid-induced events mediated on the cellular level by a receptor may enhance their effects on these cells and also other tissues

through systemic responses to eicosanoids that might occur through the cardiovascular system. Actions at these higher levels may play significant roles in the radioprotection. The success of the long-lived DiPGE₂, an analog of PGE₂, as a protective agent points to the need to develop other biologically stable eicosanoid analogs that retain radioprotective efficacy with minimal side effects.

Tumors secreting biological mediators with protective activity may modify the efficacy of the therapy. This appears to be the case for several of the prostaglandin-secreting tumors (37). The prostaglandin may conceivably protect the tumor at the cellular level by elevation of cyclic AMP (5,31) or glutathione (38), or at a systemic level by suppression of the immune system (1). An interesting set of experiments relating to this issue were conducted using the HSDM1C1 mouse fibrosarcoma cell line, which has been shown to secrete high levels of PGE₂ (38). Radiation clonogenic survival curves were performed in the presence or absence of flurbiprofen, a cyclooxygenase inhibitor. The two survival curves do not significantly differ, and may indicate that the PGE₂ produced by this tumor cell line does not feed back and modify its own cellular radiosensitivity. It is not known whether this cell line has receptors to PGE₂, and if the radioprotection is receptor mediated, then the lack of PGE₂ receptors may explain the inability of PGE₂ to act as a radioprotectant in this cell line.

ACKNOWLEDGMENTS

This research was supported by the Armed Forces Radiobiology Research Institute (AFRRI), Defense Nuclear Agency, under Research Work Unit 000153. The views presented in this paper are those of the authors; no endorsement by the Defense Nuclear Agency has been given or should be inferred. Any AFRRI research included in this review was performed according to the principles enunciated in the "Guide for the Care and Use of Laboratory Animals," prepared by the Institute of Laboratory Animal Resources, National Research Council.

REFERENCES

1. Trocha, P. J., and Catravas, G. N. Prostaglandins, lysosomes, and radiation injury. In: "Advances in Prostaglandin and Thromboxane Research," Volume 7. B. Samuelsson, P. W. Ramwell, and R. Paoletti, eds. Raven Press, New York, 1980, pp. 851-856.
2. Bito, L. Z., and Klein, E. M. The role of arachidonic acid cascade in the species-specific X-ray-induced inflammation of the rabbit eye. *Invest. Ophthalmol. Vis. Sci.* 22: 579-587, 1982.
3. Northway, M. G., Libshitz, H. I., Osborne, B. M., Feldman, M. S., Mamel, J. J., West, J. H., and Szwarc, I. A. Radiation esophagitis in the opossum: Radioprotection with indomethacin. *Gastroenterology* 78: 883-892, 1980.

4. Hanson, W. R., and Ainsworth, E. J. 16,16-Dimethyl prostaglandin E₂ induces radioprotection in murine intestinal and hematopoietic stem cells. *Radiat. Res.* 103: 196-203, 1985.
5. Walden, T. L., Jr., Patchen, M. L., and Snyder, S. L. 16,16-Dimethyl prostaglandin E₂ increases survival in mice following irradiation. *Radiat. Res.* 109: 440-448, 1987.
6. Prasad, K. N. Radioprotective effect of prostaglandin and an inhibitor of cyclic nucleotide phosphodiesterase on mammalian cells in culture. *Int. J. Radiat. Biol.* 22: 187-189, 1972.
7. Ogburn, P. L., and Brenner, W. E. "The Physiologic Actions and Effects of Prostaglandins." UpJohn, Kalamazoo, 1981.
8. Camp, R. D., Greaves, M. W., Hensby, C. N., Plummer, N. A., and Warin, A. P. Irradiation of human skin by short wavelength ultraviolet radiation (100-290 nm) (u.v.C): Increased concentrations of arachidonic acid and prostaglandins E₂ and F_{2a}. *Br. J. Clin. Pharmac.* 6: 145-148, 1978.
9. Black, A. K., Greaves, M. W., Hensby, C. N., Plummer, N. A., and Warin, A. P. The effects of indomethacin on arachidonic acid and prostaglandins E₂ and F_{2a} levels in human skin 24 hours after u.v.B. and u.v.C. irradiation. *Br. J. Clin. Pharmac.* 6: 261-266, 1978.
10. Snyder, D. S. Effect of topical indomethacin on UVR-induced redness and prostaglandin E levels in sunburned guinea pig skin. *Prostaglandins* 11: 631-643, 1976.
11. Polgar, P., Hahn, G., and Taylor, L. Radiation effects on eicosanoid formation. In: "Biochemistry of Arachidonic Acid Metabolism." W. E. M. Lands, ed. Kluwer Academic Publishers, Boston, 1985, pp. 161-173.
12. Ts'ao, C. H., Ward, W. F., and Port, C. D. Radiation injury in rat lung. I. Prostacyclin (PGI₂) production, arterial perfusion and ultrastructure. *Radiat. Res.* 96: 284-293, 1983.
13. Ziboh, V. A., Mallia, C., Morhart, E., and Taylor, J. R. Induced biosynthesis of cutaneous prostaglandins by ionizing radiation. *Proc. Soc. Exp. Biol. Med.* 169: 386-391, 1982.
14. Tanner, N. S., Stamford, I. F., and Bennett, A. Plasma prostaglandins in mucositis due to radiotherapy and chemotherapy for head and neck cancer. *Br. J. Cancer* 43: 767-771, 1981.
15. Eisen, V., and Walker, D. I. Effect of ionizing radiation on prostaglandin-like activity in tissues. *Br. J. Pharmac.* 57: 527-532, 1976.
16. Steel, L. K., Rafferty, M. A., Wolfe, W. W., Egan, J. E., Kennedy, D. A., Catravas, G. N., Jackson, W. E., III, and Dooley, M. A. Urinary excretion of cyclic nucleotides, creatinine, prostaglandin E₂, and thromboxane B₂ from mice exposed to whole-body irradiation from an enhanced neutron field. *Int. J. Radiat. Biol.* 50: 695-715, 1986.
17. Trocha, P. J., and Catravas, G. N. Effect of radioprotectant WR2721 on cyclic nucleotides, prostaglandins, and lysosomes. *Radiat. Res.* 94: 239-251, 1983.
18. Allen, J. B., Sagerman, R. H., and Stuart, M. J. Irradiation decreases vascular prostacyclin formation with no concomitant effect on platelet thromboxane production. *Lancet* 2: 1193-1195, 1981.

19. Pausescu, E., Chirvasie, R., Popescu, M.-V., and Tedodsiu, T. Dynamics of the changes in the cerebral amounts of cyclic AMP and some prostaglandins during cobalt-60 gamma-radiation-induced brain edema. *Physiologie* 14: 283-289, 1977.
20. Rubin, D. B., Drab, E. A., Ts'ao, C. H., Gardner, D., and Ward, W. F. Prostacyclin synthesis in irradiated endothelial cells cultured from bovine aorta. *J. Appl. Physiol.* 58: 592-597, 1985.
21. Steel, L. K., Sweedler, I. K., and Catravas, G. N. Effects of ^{60}Co radiation on synthesis of prostaglandins F_{2a}, E, and thromboxane B₂ in lung airways of the guinea pigs. *Radiat. Res.* 94: 156-165, 1983.
22. Gal, D., Strickland, D. M., Lifshitz, S., Buchsbaum, H. J., and Mitchell, M. D. Effect of radiation on prostaglandin production by human bowel *in vitro*. *Int. J. Radiat. Oncol. Biol. Phys.* 10: 653-657, 1984.
23. Donlon, M., Steel, L. K., Helgeson, E. A., Shipp, A., and Catravas, G. N. Radiation induced alterations in prostaglandin excretion in the rat. *Life Sci.* 32: 2631-2639, 1983.
24. Walker, D. I., and Eisen, V. Effect of ionizing radiation on 15-hydroxy prostaglandin dehydrogenase (PGDH) activity in tissue. *Int. J. Radiat. Biol.* 36: 399-407, 1979.
25. Mennie, A. T., and Dalley, V. M. Aspirin in radiation-induced diarrhea. *Lancet* 1: 1131, 1973.
26. Borowska, A., Sierakowski, S., Mackowiak, J., and Wisiniewski, K. A prostaglandin-like activity in small intestine and postirradiation gastrointestinal syndrome. *Experientia* 35: 1368-1370, 1979.
27. Weissman, G. "Prostaglandins in Acute Inflammation." UpJohn, Kalamazoo, 1980.
28. Prianishikova, E. N., Zhulanova, Z. I., and Agafeva, V. S. Effect of different doses of ionizing radiation on the binding of prostaglandin E₂ in mouse tissues. *Radiobiologiya (USSR)* 26: 652-655, 1986.
29. Popisil, M., Netikova, J., and Kozubik, A. Enhancement of hematopoietic recovery by indomethacin after sublethal whole-body gamma irradiation. *Acta Radiol. Oncol.* 25: 195-198, 1987.
30. Steel, L. K., and Ledney, G. D. Effects of neutron irradiation on PGE₂ and TXB₂ levels in biological fluids: Modification by WR-2721. In: "Prostaglandins and Lipid Metabolism in Radiation Injury." T. L. Walden and H. N. Hughes, eds. Plenum Press, New York, 1987 (this volume).
31. Lehnert, S. Modification of postirradiation survival of mammalian cells by intracellular cyclic AMP. *Radiat. Res.* 62: 107-116, 1975.
32. Hanson, W. R., Houseman, K. A., and Collins, P. W. *In vivo* radiation protection by prostaglandins and related compounds of the arachidonic acid cascade. *Pharmacol. Ther.*, in press.
33. Landauer, M. R., Walden, T. L., Davis, H. D., and Dominitz, J. A. Alterations in locomotor activity induced by radioprotective doses of 16,16-dimethyl prostaglandin E₂. In: "Prostaglandins and Lipid Metabolism in Radiation Injury." T. L. Walden and H. N. Hughes, eds. Plenum Press, New York, 1987 (this volume).

34. Black, A. K., Barr, R. M., Wong, E., Brain, S., Greaves, A. W., Dickinson, R., Shroot, B., and Hensby, C. N. Lipoxygenase products of arachidonic acid in human inflamed skin. *Br. J. Clin. Pharmacol.* 20: 185-190, 1985.
35. Kerdel, F. A., Soter, N. A., and Lim, H. W. *In vivo* mediator release and degranulation of mast cells in hematoporphyrin derivative-induced phototoxicity in mice. *J. Invest. Dermatol.* 88: 277-280, 1987.
36. Walden, T. L., Jr., Holahan, E. V., and Catravas, G. N. Development of a model system to study leukotriene-induced modification of radiation sensitivity in mammalian cells. *Prog. Lipid Res.* 25: 587-590, 1986.
37. Bennett, A. Cancer. In: "Biological Protection With Prostaglandins," Volume I. M. M. Cohen, ed. CRC Press, Boca Raton, Florida, 1986, pp. 73-80.
38. Millar, B. C., and Jinks, S. Do prostaglandins affect cellular radiosensitivity *in vitro*? *Int. J. Radiat. Biol.* 46: 367-373, 1984.
39. Weeks, J. R., Ducharme, D. W., Magee, W. E., and Miller, W. L. The biological activity of the (15S)-15-methyl analogs of prostaglandin E2 and F2. *J. Pharmac. Exp. Ther.* 186: 67-74, 1973.

UNCLASSIFIED

SECURITY CLASSIFICATION OF THIS PAGE

ADA192775

REPORT DOCUMENTATION PAGE

1a. REPORT SECURITY CLASSIFICATION UNCLASSIFIED			1b. RESTRICTIVE MARKINGS		
2a. SECURITY CLASSIFICATION AUTHORITY			3. DISTRIBUTION/AVAILABILITY OF REPORT Approved for public release; distribution unlimited.		
2b. DECLASSIFICATION/DOWNGRADING SCHEDULE			5. MONITORING ORGANIZATION REPORT NUMBER(S)		
4. PERFORMING ORGANIZATION REPORT NUMBER(S) AFRRI Scientific Reports SR87-49			7a. NAME OF MONITORING ORGANIZATION		
6a. NAME OF PERFORMING ORGANIZATION Armed Forces Radiobiology Research Institute		6b. OFFICE SYMBOL (If applicable) AFRRI	7b. ADDRESS (City, State and ZIP Code)		
6c. ADDRESS (City, State and ZIP Code) Defense Nuclear Agency Bethesda, MD 20814-5145			9. PROCUREMENT INSTRUMENT IDENTIFICATION NUMBER		
8a. NAME OF FUNDING/SPONSORING ORGANIZATION Defense Nuclear Agency		8b. OFFICE SYMBOL (If applicable) DNA	10. SOURCE OF FUNDING NOS.		
8c. ADDRESS (City, State and ZIP Code) Washington, DC 20305			PROGRAM ELEMENT NO. NWED QAXM	PROJECT NO.	TASK NO.
11. TITLE (Include Security Classification) (See cover.)			WORK UNIT NO. 000153		
12. PERSONAL AUTHOR(S) Walden, T. L.					
13a. TYPE OF REPORT Reprint		13b. TIME COVERED FROM _____ TO _____		14. DATE OF REPORT (Yr., Mo., Day) Book - 1987	
15. PAGE COUNT 9					
16. SUPPLEMENTARY NOTATION Published in <u>Prostaglandin and Lipid Metabolism in Radiation Injury</u> . (Book)					
17. COSATI CODES			18. SUBJECT TERMS (Continue on reverse if necessary and identify by block number)		
FIELD	GROUP	SUB. GR.			
19. ABSTRACT (Continue on reverse if necessary and identify by block number)					
20. DISTRIBUTION/AVAILABILITY OF ABSTRACT UNCLASSIFIED/UNLIMITED ☒ SAME AS RPT. ☐ DTIC USERS ☐			21. ABSTRACT SECURITY CLASSIFICATION UNCLASSIFIED		
22a. NAME OF RESPONSIBLE INDIVIDUAL Junith A. Van Deusen			22b. TELEPHONE NUMBER (Include Area Code) (202) 295-3536		22c. OFFICE SYMBOL ISDP